Russell Investments Group Ltd. Purchases 120,648 Shares of Boston Scientific Corporation $BSX

Russell Investments Group Ltd. lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 9.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,442,640 shares of the medical equipment provider’s stock after buying an additional 120,648 shares during the quarter. Russell Investments Group Ltd.’s holdings in Boston Scientific were worth $154,818,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of BSX. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. Avantax Advisory Services Inc. lifted its stake in shares of Boston Scientific by 17.0% in the 1st quarter. Avantax Advisory Services Inc. now owns 42,616 shares of the medical equipment provider’s stock valued at $4,299,000 after purchasing an additional 6,200 shares during the period. LPL Financial LLC boosted its position in shares of Boston Scientific by 0.4% during the 1st quarter. LPL Financial LLC now owns 1,124,011 shares of the medical equipment provider’s stock valued at $113,390,000 after purchasing an additional 4,994 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in Boston Scientific by 4.2% during the first quarter. Sheaff Brock Investment Advisors LLC now owns 6,556 shares of the medical equipment provider’s stock worth $661,000 after purchasing an additional 266 shares during the period. Finally, Foundations Investment Advisors LLC increased its holdings in Boston Scientific by 8.7% in the first quarter. Foundations Investment Advisors LLC now owns 3,599 shares of the medical equipment provider’s stock worth $363,000 after purchasing an additional 288 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $101.37 on Wednesday. The stock has a market cap of $150.27 billion, a price-to-earnings ratio of 54.21, a PEG ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The firm’s 50-day simple moving average is $98.98 and its 200 day simple moving average is $102.30.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.